With readout of Apollo-B approaching, can Onpattro succeed where Bridgebio’s acoramidis failed?
New Amsterdam wants to prove that the ill-fated mechanism has a role in cardiovascular disease – and this time it’s all about the bad cholesterol.
Remember Nanostim? It’s back – in a modified form, sold by a different company, and under another name.
A correction – as long as it is not too severe – might not be a bad thing for the sector.
The group highlights its ambitions in cancer again, but is at least two years away from launching a new product.